Avalyn Pharma bolsters balance sheet with $345 million IPO, projects runway into 2029
Avalyn Pharma (NASDAQ:AVLN) provided a comprehensive update on its financial position and clinical development programs for the first quarter of 2026, underscored by a strengthened capital base following its recent initial public offering.










